Physician profile
Derek Lin
NPI 1740523794
$5,367.16
in general payments reported to CMS, 2019-2025
29 companies · $2,445 in 2025
The $2,445 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2023: $512 · 2024: $2,006 · 2025: $2,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,945 · Education: $17.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,945.01 |
| Education | $17.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,112.02 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $728.34 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $398.00 | 2023-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $336.58 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $316.37 | 2024-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $291.20 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Qol Medical, LLC | $244.36 | 2023-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $223.74 | 2024-2025 | Omvoh |
| Aries Pharmaceuticals, INC. | $190.74 | 2019 | |
| Madrigal Pharmaceuticals | $176.92 | 2024-2025 | Rezdiffra, Resmetirom |
| Celltrion USA INC. | $154.36 | 2024-2025 | Vegzelma, Zymfentra |
| Boston Scientific Corporation | $147.92 | 2024 | Cre Pro |
| Ardelyx, INC. | $145.10 | 2024-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $137.81 | 2024-2025 | Zenpep, Vowst |
| Genzyme Corporation | $108.80 | 2023-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $94.38 | 2024-2025 | Voquezna |
| Celgene Corporation | $87.47 | 2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $79.20 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $78.81 | 2023-2024 | Dificid |
| Neuraxis, INC. | $77.59 | 2025 | |
| Ironwood Pharmaceuticals, INC | $50.08 | 2023 | Linzess |
| Ferring Pharmaceuticals INC. | $42.33 | 2024 | Rebyota |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.01 | 2023 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $28.42 | 2023 | Zeposia |
| Mauna Kea Technologies, INC. | $20.75 | 2025 | |
| Shionogi INC | $15.81 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $14.76 | 2025 | Iqirvo |
| Enterra Medical, INC. | $13.28 | 2024 | |
| Evoke Pharma, INC. | $13.01 | 2023 | Gimoti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.